-
The Safety of Flunixin meglumine
Time of Update: 2023-04-30
Overall, the safety of flunixin meglumine is an important consideration in the chemical industry, and it is a key factor that makes it a popular choice for use in a variety of applications.
-
The "unlimited cancer" therapy track is winding: Merck, Eli Lilly, Novartis lead, and the cornerstone comes later
Time of Update: 2022-10-19
In March 2021, platinib was approved for the first time in China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received platinum-containing chemotherapy with transfection rearrangement (RET) gene fusion, becoming the first highly selective RET inhibitor approved for marketing in China.
-
How to use constipated irritable bowel syndrome? AGA guides teach you to do
Time of Update: 2022-10-01
Q7: Should tricyclic antidepressants be used in patients with IBS-C?A7: Conditional recommendation [reason]: Studies have shown that TCAs provide significant relief from abdominal pain symptoms compared with placebo.
-
Celestial Biologics was approved by the CDE to conduct a Phase 3 registered clinical trial of lyzolizumab combined with azacitidine for the treatment of HR-MDS
Time of Update: 2022-09-21
/* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prnews
-
The medical insurance negotiation declaration is in full swing
Time of Update: 2022-08-15
0 1 Reasonable competition and standard price Encourage horizontal comparison of products As in previous years, this year's medical insurance negotiation work is still divided into five stages: preparation, declaration, expert review, negotiation/bidding, and announcement of results .
-
The health and health commission's rectification storm is coming
Time of Update: 2022-05-19
Key point 6: Strictly prohibit excessive charges for nucleic acid testing The "Plan" will focus on in-depth special actions against crimes involving new coronary pneumonia vaccines in medical institutions at all levels and various types, and severely crack down on the production and sale of counterfeit products, illegal operations, smuggling, and vaccination in the field of vaccines in accordance with the law.
-
Ministry of Ecology and Environment: Focusing on the chemical industry and other industries, implement 100 soil pollution source control projects
Time of Update: 2022-05-08
" According to Su Kejing, in recent years, the Ministry of Ecology and Environment has cooperated closely with relevant departments, and mainly adopted the following measures, which can be summarized in nine words: building a list, strict access, and risk prevention .
-
AstraZeneca over US$3.5 billion and Ionis to develop a new antisense oligonucleotide drug under development
Time of Update: 2021-12-31
On December 7, AstraZeneca and Ionis Pharmaceuticals (hereinafter referred to as "Ionis") announced that an antisense oligonucleotide (ASO) eplontersen (IONIS-TTR-LRX) of the latter under development has reached over 35.
Billion-dollar global development and commercialization agreement .
Eplontersen is the fifth drug developed by Ionis and AstraZeneca.
-
Huahai Pharmaceutical's preparation product Acyclovir ointment was approved by the U.S. FDA
Time of Update: 2021-12-06
Acyclovir ointment was developed by Bausch Health US and was first marketed in the United States in 1982 .
-
The US FDA approves Cyltezo (adalimumab-adbm) as the first biosimilar that is interchangeable with Humira
Time of Update: 2021-11-02
The additional studies showed that Cyltezo with Humira equivalent pharmacokinetics between the treatment group and converting the continuous treatment group, efficacy, immunological no significant differences in immunogenicity and safety , the results have been published in the American Academy of Dermatology Society meeting in 2021 .
-
The State Food and Drug Administration approves Hengrui Pharmaceuticals Pregabalin Sustained-Release Tablets for the treatment of chronic neuropathic pain in adults
Time of Update: 2021-10-09
On September 28, the official website of the National Food and Drug Administration (NMPA) announced that the pregabalin sustained-release tablets declared by Hengrui Medicine had been approved for listing in China .
-
Allogene's universal BCMA CAR-T cells obtained the U.S. FDA fast-track designation medical Maimeng broke the news
Time of Update: 2021-08-22
Recommended reading: ASCO 2021: Allogene announces the latest clinical data of two allogeneic CD19 CAR-T drug treatments Yimai Meng broke the news that BCMA: MM's popular target Multiple myeloma (MM) is a clonal plasma cell abnormality The proliferative malignant disease is also the second most common hematological malignancy after non-Hodgkin’s lymphoma.
-
Biogen's new clinical study of subcutaneous injection of aducanumab
Time of Update: 2021-08-08
The main purpose of this trial is to evaluate the absolute bioavailability of a single subcutaneous injection of fixed-dose aducanumab (BIIB037) and a single weight-based intravenous (IV) aducanumab in healthy volunteers.
-
A new anti-gout drug has exploded
Time of Update: 2021-07-27
The fastest research and development is Hengrui Medicine's SHR4640 tablets, which is currently undergoing phase III clinical trials in China and is expected to become the first domestically approved Class 1 new drug in the field of anti-gout .
-
Sanofi China's first global research institute opened
Time of Update: 2021-07-10
He said: "The opening of Sanofi China Research Institute will promote biological The collaboration between pharmaceutical companies, Chinese academia, scientific research circles and clinical institutions has deepened to promote the development of an innovative ecosystem and help Suzhou build a new highland for the concentration of the biopharmaceutical industry .
